Egetis Therapeutics AB (publ) (STO:EGTX)

Market Cap	2.11B
Revenue (ttm)	55.40M
Net Income (ttm)	-333.30M
Shares Out	395.16M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	22.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364,780
Average Volume	933,330
Open	5.29
Previous Close	5.28
Day's Range	5.20 - 5.35
52-Week Range	3.03 - 7.28
Beta	1.26
RSI	55.11
Earnings Date	Feb 26, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 40
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EGTX

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.